Chickenpox (varicella) and shingles (herpes zoster) are caused by the varicella-zoster virus; chickenpox is the acute invasive phase of the virus, and shingles represents reactivation of the latent phase.
For more information, see Zoster (Shingles) Advisory Committee on Immunization Practices Vaccine Recommendations and Centers for Disease Control and Prevention (CDC): Shingles (Herpes Zoster) Vaccination.
(See also Overview of Immunization.)
Contraindications for the recombinant zoster vaccine include
A severe allergic reaction (eg, anaphylaxis) to a vaccine component or after a previous dose of the vaccine
Contraindications for the live-attenuated zoster vaccine include
A severe allergic reaction (eg, anaphylaxis) to a vaccine component
Known severe primary or acquired immunodeficiency (eg, due to leukemia, lymphomas, solid tumors, tumors that affect bone marrow or the lymphatic system, AIDS, severe HIV infection, treatment with chemotherapy, or long-term use of immunosuppressants)
Moderate or severe acute illness with or without fever (vaccination is postponed until illness resolves)
For the live-attenuated zoster vaccine, use of specific antiviral drugs: acyclovir, famciclovir, or valacyclovir (if possible, vaccination is postponed until 24 hours after use of these drugs, and the drugs are not resumed for 14 days after vaccination)
Clinical trials for the recombinant vaccine excluded pregnant women and women who are breastfeeding. The CDC recommends to consider delaying administration of the recombinant vaccine until after pregnancy and breastfeeding. (See also CDC: Shingrix Recommendations.)
The recombinant zoster vaccine dose is given IM in 2 doses (0.5 mL each), 2 to 6 months apart.
For adults who previously received the live-attenuated zoster vaccine, 2 doses of the recombinant vaccine are given 2 to 6 months apart and ≥ 2 months after the live-attenuated vaccine was given.
The live-attenuated zoster vaccine is given as a single 0.65-mL subcutaneous dose in the deltoid region of the upper arm.
Zoster vaccine should be given ≥ 14 days before immunosuppressive therapy is begun; some experts prefer waiting 1 month after zoster vaccination to begin immunosuppressive therapy if possible.
The most common adverse effects of the recombinant zoster vaccine are pain, redness, and swelling at the injection site and myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.
The most common adverse reactions of the live-attenuated zoster vaccine are soreness, redness, swelling, and itching at the injection site and headache.
The following are some English-language resources that may be useful. Please note that THE MANUAL is not responsible for the content of these resources.
Drugs Mentioned In This Article
|Drug Name||Select Trade|